Addex Therapeutics ( (CH:ADXN) ) just unveiled an update.
Addex Therapeutics announced it will release its Full-Year 2024 Financial Results on April 25, 2025, accompanied by a business update and product pipeline review by CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market position and investor confidence.
More about Addex Therapeutics
Addex Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel small molecule allosteric modulators for neurological disorders. Its lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, while it also has programs for substance use disorders and chronic cough. Addex holds a 20% equity interest in Neurosterix LLC, which is advancing several allosteric modulator programs. The company’s shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol ‘ADXN’.
Average Trading Volume: 100
Current Market Cap: $34.8M
See more data about ADXN stock on TipRanks’ Stock Analysis page.